Sitagliptin, a modern antidiabetic agent which is weight neutral and associated with low rate of hypoglycaemias, is being increasingly used in type 2 diabetes mellitus (DM). However, there is a paucity of data about its efficacy and safety in beta-thalassaemia major (β-TM). This retrospective case series of five patients (mean age of 45 years) is the first study evaluating the use of sitagliptin in patients with β-TM and DM. Four patients responded well to sitagliptin, as evidenced by a decrease in fructosamine by 77 and 96μmol/L (equivalent reduction in HbA1c of 1.5

作者：Shahrzad, Zonoozi；Maria, Barnard；Emma, Prescott；Romilla, Jones；Farrukh T, Shah；Ploutarchos, Tzoulis

来源：Mediterranean journal of hematology and infectious diseases 2017 年 9卷 1期